GENFLEET-B(02595.HK)

GenFleet Therapeutics (Shanghai) Inc. operates as a biopharmaceutical company that focuses on developing novel treatment options in the fields of oncology that cover different lines of treatments of multiple solid tumors, as well as autoimmune and inflammatory diseases in the People's Republic of China and internationally. The company’s products include GFH925, help for the treatment of advanced non-small cell lung cancer, and GFH375, an orally bioavailable small molecule inhibitor of Kirsten rat sarcoma (KRAS) G12C. It product under development GFH276, which is in Phase I clinical trials for the treatment of Solid tumors; GFS202A, which is in Phase I clinical trials for the treatment of Cachexia; GFH009, which is in Phase II clinical trials for the treatment of AML; and GFH312, which is in Phase I clinical trials for the treatment of PAD with IC, PBC.